Autism Spectrum Disorder (ASD) Clinical Trial
Official title:
Electrophysiological Markers for Interventions in Phelan-McDermid Syndrome and Idiopathic Autism
This clinical trial will use growth hormone as a novel treatment for Phelan-McDermid syndrome (PMS) and idiopathic autism. A double-blind, placebo-controlled crossover trial design will be used in 30 children with idiopathic autism and 15 children with PMS to evaluate the the effects of growth hormone on visual evoked potentials (VEPs), socialization, language, and repetitive behaviors. The researchers expect to provide evidence for the feasibility of using VEPs in PMS, and to show support for growth hormone in ameliorating clinical symptoms of ASD.
This study will show that select electrophysiological markers in PMS are relevant to iASD and predictive of treatment response with growth hormone. The long-term goal is to optimize treatment selection in iASD by establishing biological signature(s) derived from PMS. The expected outcome is to establish the feasibility of electrophysiological biomarkers for use in clinical trials in PMS and iASD, demonstrate efficacy of growth hormone in PMS and iASD, and to define a biological profile that will mark a subset of patients with iASD likely to show clinical response to growth hormone. The study will enroll 45 children (15 PMS; 30 iASD; age 2-12 years) and administer growth hormone/placebo as once daily subcutaneous injection for 12 weeks at standard doses. The study team will monitor baseline anthropometric measures, laboratory parameters for growth, IGF-1 levels, and bone age throughout the study. Evaluations will include validated behavioral scales. Visual evoked potentials (VEPs) will be used as biomarkers of visual sensory reactivity. Growth Hormone is approved by the FDA for the treatment of children with short stature due to primary growth hormone deficiency, among several other indications. It is being used off-label in the current study and is not FDA approved for use in PMS or ASD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03715166 -
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
|
Phase 3 | |
| Not yet recruiting |
NCT05182697 -
SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
|
N/A | |
| Completed |
NCT02803801 -
Build Your Parenting Toolkit: Guiding Children to Become Flexible Thinkers
|
N/A | |
| Recruiting |
NCT04376151 -
Guided ACT and for Adults With ASD
|
N/A | |
| Terminated |
NCT03715153 -
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
|
Phase 3 | |
| Terminated |
NCT01592773 -
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
|
Phase 2 | |
| Withdrawn |
NCT01395953 -
Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders
|
Phase 2 | |
| Terminated |
NCT01248130 -
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
|
Phase 2 | |
| Completed |
NCT04860986 -
A Repeatability and Reproducibility Study of the EarliPoint™ Device
|
||
| Completed |
NCT04299464 -
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
|
Phase 2 | |
| Recruiting |
NCT03392870 -
Evaluation of a Clinical Transitional Program in Autism
|
N/A | |
| Completed |
NCT01592786 -
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
|
Phase 2 | |
| Completed |
NCT04631432 -
Choice Switching and Autism
|
||
| Recruiting |
NCT04578756 -
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
|
Phase 3 | |
| Recruiting |
NCT06443320 -
Evaluation of the Videodrama Therapeutic Device for Children With Autism Spectrum Disorders
|
N/A | |
| Completed |
NCT02037022 -
Pivotal Response Treatment Package for Young Children With Autism
|
N/A | |
| Completed |
NCT01854346 -
Social Skills Group Training ("KONTAKT") for Children and Adolescent With High-functioning Autism Spectrum Disorders
|
N/A | |
| Active, not recruiting |
NCT04895215 -
AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)
|
Phase 2 | |
| Active, not recruiting |
NCT03426826 -
The Gut-Brain Study
|
Phase 1 | |
| Completed |
NCT02384486 -
Efficacy of Training Programme to Reduce Stress
|
N/A |